These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14513812)

  • 21. Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B.
    Bhattacharyya A; Bajpai M
    Curr Drug Deliv; 2013 Oct; 10(5):542-7. PubMed ID: 23675913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.
    Hussain A; Singh VK; Singh OP; Shafaat K; Kumar S; Ahmad FJ
    Drug Deliv; 2016 Oct; 23(8):3101-3110. PubMed ID: 27854145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel.
    Kang JW; Davaa E; Kim YT; Park JS
    J Drug Target; 2010 Sep; 18(8):637-44. PubMed ID: 20192816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and nephrotoxicity of amphotericin B-incorporated poly(ethylene glycol)-block-poly(N-hexyl stearate l-aspartamide) micelles.
    Diezi TA; Takemoto JK; Davies NM; Kwon GS
    J Pharm Sci; 2011 Jun; 100(6):2064-70. PubMed ID: 21491436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanocarrier-based topical drug delivery for an antifungal drug.
    Hussain A; Samad A; Nazish I; Ahmed FJ
    Drug Dev Ind Pharm; 2014 Apr; 40(4):527-41. PubMed ID: 23627443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender differences in acute toxicity, toxicokinetic and tissue distribution of amphotericin B liposomes in rats.
    Wang D; Zhang W; Ju JX; Wang LJ; Huang RY; Xu YF; Zhang HL; Qi JL
    Toxicol Lett; 2021 Mar; 338():78-84. PubMed ID: 33309996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of amphotericin B liposome formulations.
    Manosroi A; Kongkaneramit L; Manosroi J
    Drug Dev Ind Pharm; 2004 May; 30(5):535-43. PubMed ID: 15244089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
    Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
    Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
    Matsui S; Imai S; Yabuki M; Komuro S
    Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cholesterol on the release of amphotericin B from PEG-phospholipid micelles.
    Vakil R; Kwon GS
    Mol Pharm; 2008; 5(1):98-104. PubMed ID: 18159926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
    Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
    Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug delivery system of anti-fungal and parasitic agents.
    Maesaki S
    Curr Pharm Des; 2002; 8(6):433-40. PubMed ID: 12069380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
    Azanza JR; Sádada B; Reis J
    Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
    Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
    Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.
    Townsend RW; Zutshi A; Bekersky I
    Drug Metab Dispos; 2001 May; 29(5):681-5. PubMed ID: 11302934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system.
    Hong MS; Lim SJ; Oh YK; Kim CK
    J Pharm Pharmacol; 2002 Jan; 54(1):51-8. PubMed ID: 11829129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel delivery system for amphotericin B with lipid nano-sphere (LNS).
    Fukui H; Koike T; Saheki A; Sonoke S; Seki J
    Int J Pharm; 2003 Oct; 265(1-2):37-45. PubMed ID: 14522116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular localization and state of amphotericin B in PEG liposomes.
    Moribe K; Maruyama K; Iwatsuru M
    Int J Pharm; 1999 Dec; 193(1):97-106. PubMed ID: 10581426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.